Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Background & aims Ursodeoxycholic acid (UDCA) is used for treatment of primary biliary cirrhosis. Previous studies showed that, compared with UDCA monotherapy, bile salts plus prednisolone had no further effect on laboratory data but improved liver histology. Thirty percent of these patients had prednisolone-related side effects. Budesonide is a glucocorticoid with a high receptor affinity and a high first-pass metabolism. In this study we investigated whether budesonide and UDCA are superior to UDCA monotherapy.Methods A 2-year prospective, controlled double-blind trial was performed. Twenty patients (mainly with early-stage disease) were treated with UDCA at a dose of 10-15 mg/kg daily in addition to 3 mg budesonide 3 times daily (group A), and 19 patients (1 dropped out for personal reasons) were treated with UDCA plus placebo (group B). Liver biopsy specimens were taken before, after 12 months, and at the end of study. Glucose tolerance tests, serum cortisol levels, and adrenocorticotropin-stimulated cortisol secretion were assessed at regular intervals. Bone mass density was measured by dual-energy photon absorptiometry.Results Compared with pretreatment values, liver enzyme and immunoglobulin M and G levels decreased significantly in both groups. Improvement in group A was significantly more pronounced (P < 0.05) than in group B. Titers of antimitochondrial antibodies did not change. In group A, the point score of liver histology improved by 30.3%; in group B, it deteriorated by 3.5% (P < 0.001). Changes in bone mineral density after 2 years were -1.747% in group A and -0.983% in group B (P = 0.43). Budesonide had little influence on the hypothalamic-pituitary-adrenal axis. One patient in group A had budesonide-related side effects; in 3 patients in group B, complications of liver disease developed.Conclusions Combination therapy with UDCA and budesonide is superior to UDCA and placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A randomised placebo-controlled trial (n=39) was the first to study budesonide (9 mg/day) as add-on therapy to UDCA in patients with early-stage PBC.159 Over the 2-year study period, patients with combination therapy exhibited a significant reduction in serum ALP as well as improvement in liver histology according to the Ludwig classification system.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [159]
Experimental — accuracy not yet measuredIn the citing paper
“However, immunosuppression alone is insufficient for treating PBC patients [180].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diseases of the Liver and Biliary System
(2001) · Wiley eBooks · doi:10.1002/9780470986820 · Cited by 1,825
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
Leuschner, U., Fischer, H., Kurtz, W., Güldütuna, S., Hübner, K., Hellstern, A., Gatzen, M., & Leuschner, M. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91698-3 · Cited by 353
Self-citationPharmacokinetics and metabolism of budesonide, a selective glucocorticoid.
Ryrfeldt, Å., Andersson, P., Edsbäcker, S., Tönnesson, M., Davies, D., & Pauwels, R. (1982) · PubMed · Cited by 301
COMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Inflammatory Bowel Disease: From Bench to Bedside
(2003) · Springer eBooks · doi:10.1007/978-1-4020-3477-0 · Cited by 227
Research works printed but not linked: 2
- David, 1985, Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten. Eine Pilotstudie (abstr), Z Gastroenterol, 23, 420
- Wür thwein, 1992, Lipophilicity and receptor affinity of glucocorticoids, Pharm Ztg Wiss, 137, 161
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“Budesonide in combination with UDCA showed favorable results on biochemical and histological parameters in early-stage disease [31,32], but not late-stage disease [33,34].”
ResultHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Metadata
- Authors
- Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U.
- Affiliations
- University Hospital Frankfurt (DE)
- Klinikum Esslingen (DE)
- Goethe University Frankfurt (DE)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1999-10
- Volume
- 117
- Issue
- 4
- Pages
- 918-925
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2075487592
- Cited by
- 247
- References
- 33
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 14 · 2017: 9 · 2016: 12 · 2015: 19 · 2014: 16 · 2013: 9 · 2012: 9
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, budesonide, ursodeoxycholic acid, combination therapy, glucocorticoids, bile salts, liver histopathology, bone mineral density, hypothalamic-pituitary-adrenal axis, antimitochondrial antibodies
- MeSH terms
- Administration, Oral, Administration, Topical, Anti-Inflammatory Agents, Cholagogues and Choleretics, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunoglobulin G, Immunoglobulin M, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Prospective Studies, Ursodeoxycholic Acid, Treatment Outcome, Budesonide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. https://app.cochat.ai/papers/10.1016/s0016-5085(99)70351-3
- The paper
- Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999). Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology. https://doi.org/10.1016/s0016-5085(99)70351-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.